In last trading session, Contineum Therapeutics Inc (NASDAQ:CTNM) saw 0.8 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $13.50 trading at $0.15 or 1.12% at ring of the bell on the day assigns it a market valuation of $348.00M. That closing price of CTNM’s stock is at a discount of -62.96% from its 52-week high price of $22.00 and is indicating a premium of 8.67% from its 52-week low price of $12.33. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.13 million shares which gives us an average trading volume of 92.37K if we extend that period to 3-months.
For Contineum Therapeutics Inc (CTNM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.44 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Contineum Therapeutics Inc (NASDAQ:CTNM) trade information
Upright in the green during last session for gaining 1.12%, in the last five days CTNM remained trading in the red while hitting it’s week-highest on Monday, 12/16/24 when the stock touched $13.50 price level, adding 7.53% to its value on the day. Contineum Therapeutics Inc’s shares saw a change of -12.34% in year-to-date performance and have moved -3.78% in past 5-day. Contineum Therapeutics Inc (NASDAQ:CTNM) showed a performance of -1.10% in past 30-days. Number of shares sold short was 1.05 million shares which calculate 13.66 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 32 to the stock, which implies a rise of 57.81% to its current value. Analysts have been projecting 32 as a low price target for the stock while placing it at a high target of 32. It follows that stock’s current price would drop -137.04% in reaching the projected high whereas dropping to the targeted low would mean a loss of -137.04% for stock’s current value.
